查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870013

美国肉牛健康市场规模、份额和趋势分析报告：按产品、分销管道和细分市场预测（2025-2033 年）

U.S. Beef Cattle Health Market Size, Share & Trends Analysis Report By Product (Biologics, Pharmaceuticals, Medicated Feed Additives), By Distribution Channel, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

美国肉牛健康市场摘要

据估计，美国肉牛健康管理市场在 2024 年的价值为 11.2 亿美元，预计到 2033 年将达到 23.5 亿美元。

预计2025年至2033年，该市场将以8.80%的复合年增长率成长。推动市场成长的因素包括感染疾病和寄生虫病的日益流行、畜群规模缩小导致人们对动物健康和生产力的日益关注，以及对预防性兽医保健投入的增加。此外，牛价上涨和生物安全问题也加速了育肥场对疫苗、诊断和健康监测技术的应用。

牛中地方性疾病和新兴疾病的日益普及是美国肉牛健康产业的主要成长要素，带动了对诊断、疫苗、治疗和预防策略的需求。例如，根据美国农业部 (USDA) 的报告，牛呼吸道疾病 (BRD) 仍然是育肥牛面临的最昂贵的健康问题之一。研究表明，降低 BRD 的死亡率和发病率可以改善动物福利，影响牛肉供应，降低成本，并对下游市场（包括牛、饲料和牛肉价格）产生影响。

另一个例子是新世界螺旋蝇的再次出现，这导致了进口禁令（例如来自墨西哥的禁令）、治疗和生物安全成本的增加，并因推高牛肉价格而威胁到供应。为了应对这个问题，畜牧生产者正在增加对动物健康基础设施的投资，包括加强监测、快速诊断、研发新型疫苗和抗寄生虫药物，以及改善畜群管理措施。这些投资正在扩大畜牧保健市场。根据美国农业部（USDA）预测，到2024年，美国将占据北美牛保健市场约87%的份额。预防医学、诊断技术、精准畜牧业和治疗药物都是美国市场中成长快速的领域。这些趋势表明，生产者和政策制定者都认识到，疾病预防对于保护牲畜、稳定市场、保障出口以及维持牛肉价格的合理性至关重要。

此外，美国食品药物管理局(FDA)核准的牛用药数量不断增加，也推动了美国肉牛健康市场的发展，扩大了生产者可选择的预防和治疗方案范围。近期核准，例如用于预防螺旋蝇的 Dectomax CA1 和用于治疗牛呼吸道疾病的 Pradarex，为牧场主提供了保护牛群健康、降低死亡率和提高生产力的实用工具。这些核准的核准促进了生物製药、药品和药用饲料的应用，使生产者能够更有效地管理疾病并减少经济损失，从而支持整体市场成长。

目录

第一章调查方法和范围

第二章执行摘要

第三章 市场变数的趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 定价分析
  • 2024年动物数量估计
  • 市场分析工具
    • 波特五力分析
    • PESTEL分析与SWOT分析

第四章：美国肉牛健康市场：依产品分類的估算与趋势分析

  • 美国肉牛健康市场按产品划分：细分仪表板
  • 美国肉牛健康市场产品波动分析
  • 按产品划分，2021-2033 年
  • 生物製药
  • 製药
  • 药品和饲料添加剂

第五章：美国肉牛健康市场：按分销管道分類的估算与趋势分析

  • 美国肉牛健康市场按分销管道划分：细分仪表板
  • 美国肉牛健康市场：按分销管道分析波动情况
  • 按分销管道划分，2021-2033 年
  • 医院/诊所药房
  • 零售
  • 电子商务

第六章 竞争情势

  • 市场参与企业分类
    • 市场领导者
    • 新兴参与者
  • 2024年市占率/评级分析（热力图分析）
  • 公司简介
    • Zoetis Inc.
    • Boehringer Ingelheim International GmbH
    • Merck &Co., Inc.
    • Virbac
    • Elanco
    • Vetoquinol SA
    • Phibro Animal Health Corporation
    • Norbrook
    • Dechra Pharmaceuticals Plc
    • Bimeda, Inc
    • Cargill, Incorporated
  • 其他主要企业名单
Product Code: GVR-4-68040-778-0

U.S. Beef Cattle Health Market Summary

The U.S. beef cattle health market size was estimated at USD 1.12 billion in 2024 and is projected to reach USD 2.35 billion by 2033, growing at a CAGR of 8.80% from 2025 to 2033. The market is experiencing growth driven by the rising prevalence of infectious and parasitic diseases, shrinking cattle herds prompting greater focus on animal health and productivity, and increasing investments in preventive veterinary care. Additionally, high cattle values and biosecurity concerns are accelerating the adoption of vaccines, diagnostics, and health monitoring technologies across beef operations.

Rising disease prevalence among cattle, both endemic and emerging, has become a major growth driver for the U.S. beef cattle health industry, pushing increased demand for diagnostics, vaccines, therapeutics, and preventive strategies. For example, as per the USDA report, Bovine Respiratory Disease (BRD) remains one of feedlot cattle's costliest health issues. Several studies show that reductions in mortality and morbidity from BRD improve animal welfare, affect beef supply, lower costs, and influence downstream markets for cattle, feed, and beef prices.

Another example is the re-emergence of the New World Screwworm, which threatens supply by prompting import bans (e.g., from Mexico), increasing treatment and biosecurity costs, and pushing beef prices upward. In response, cattle producers are investing more heavily in animal health infrastructure: enhanced surveillance, rapid diagnostics, new vaccines or antiparasitic drugs, and improved herd management practices. This investment is enlarging the cattle healthcare market. According to the USDA, in 2024, the U.S. accounted for almost 87% of the North American cattle healthcare market. Preventive healthcare, diagnostics, precision livestock farming, and therapeutics are all growing segments in the U.S. market. These trends also signal that producers and policymakers recognize disease prevention as economically essential to safeguard animals and ensure market stability, export access, and beef affordability.

Additionally, the rising number of FDA-approved drugs for beef cattle is driving the U.S. beef cattle health market, as it expands the range of available preventive and therapeutic options for producers. Recent approvals, such as Dectomax-CA1 for New World screwworm prevention and Pradalex for bovine respiratory disease, provide ranchers with practical tools to protect herd health, reduce mortality, and improve productivity. These approvals also encourage the adoption of biologics, pharmaceuticals, and medicated feed additives, enabling producers to manage disease more efficiently and mitigate economic losses, fueling overall market growth.

U.S. Beef Cattle Health Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. beef cattle health market report based on product and distribution channel:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Biologics
    • Vaccines
    • Attenuated Live Vaccines
    • Inactivated Vaccines
    • Subunit Vaccines
    • DNA Vaccines
    • Recombinant Vaccines
    • Autogenous Vaccines
    • Other Biologics
  • Pharmaceuticals
    • Parasiticides
    • Anti-infectives
    • Anti-inflammatory
    • Analgesics
    • Others
  • Medicated Feed Additives
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Retail
  • E-commerce
  • Hospital/Clinic Pharmacy

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Distribution Channel
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information/Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Model 1 Analysis
    • 1.7.2. Model 2 Analysis
    • 1.7.3. Model 3 Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary/Related Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing beef availability for domestic consumption
      • 3.2.1.2. Strong overseas demand for U.S. beef
      • 3.2.1.3. Supportive initiatives
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory challenges
      • 3.2.2.2. Adverse environmental conditions
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. Pricing Analysis
  • 3.4. Estimated Animal Population, 2024
  • 3.5. Market Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Beef Cattle Health Market: Product Estimates & Trend Analysis

  • 4.1. U.S. Beef Cattle Health Market, By Product: Segment Dashboard
  • 4.2. U.S. Beef Cattle Health Market, By Product Movement Analysis
  • 4.3. U.S. Beef Cattle Health Market Estimates & Forecasts, by Product, 2021 to 2033 (USD Million)
  • 4.4. Biologics
    • 4.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.1.1. Vaccines
        • 4.4.1.1.1. Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.1.1.2. Attenuated Live Vaccines
          • 4.4.1.1.2.1. Attenuated Live Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.1.1.3. Inactivated Vaccines
          • 4.4.1.1.3.1. Inactivated Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.1.1.4. Subunit Vaccines
          • 4.4.1.1.4.1. Subunit Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.1.1.5. DNA Vaccines
          • 4.4.1.1.5.1. DNA Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.1.1.6. Recombinant Vaccines
          • 4.4.1.1.6.1. Recombinant Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.1.1.7. Autogenous Vaccines
          • 4.4.1.1.7.1. Autogenous Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.1.2. Other Biologics
        • 4.4.1.2.1. Other Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Pharmaceuticals
    • 4.5.1. Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.1.1. Parasiticides
        • 4.5.1.1.1. Parasiticides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.1.2. Anti-infectives
        • 4.5.1.2.1. Anti-infectives Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.1.3. Anti-inflammatory
        • 4.5.1.3.1. Anti-inflammatory Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.1.4. Analgesics
        • 4.5.1.4.1. Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.1.5. Others
        • 4.5.1.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Medicated Feed Additives
    • 4.6.1. Medicated Feed Additives Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Beef Cattle Health Market: By Distribution Channel Estimates & Trend Analysis

  • 5.1. U.S. Beef Cattle Health Market, By Distribution Channel: Segment Dashboard
  • 5.2. U.S. Beef Cattle Health Market, By Distribution Channel Movement Analysis
  • 5.3. U.S. Beef Cattle Health Market Estimates & Forecasts, by Distribution Channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital/Clinic Pharmacy
    • 5.4.1. Hospital/Clinic Pharmacy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Retail
    • 5.5.1. Retail Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. E-commerce
    • 5.6.1. E-commerce Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Market Participant Categorization
    • 6.1.1. Market Leaders
    • 6.1.2. Emerging Players
  • 6.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
  • 6.3. Company Profiles
    • 6.3.1. Zoetis Inc.
      • 6.3.1.1. Participant's Overview
      • 6.3.1.2. Financial Performance
      • 6.3.1.3. Product/Service Benchmarking
      • 6.3.1.4. Strategic Initiatives
    • 6.3.2. Boehringer Ingelheim International GmbH
      • 6.3.2.1. Participant's Overview
      • 6.3.2.2. Financial Performance
      • 6.3.2.3. Product/Service Benchmarking
      • 6.3.2.4. Strategic Initiatives
    • 6.3.3. Merck & Co., Inc.
      • 6.3.3.1. Participant's Overview
      • 6.3.3.2. Financial Performance
      • 6.3.3.3. Product/Service Benchmarking
      • 6.3.3.4. Strategic Initiatives
    • 6.3.4. Virbac
      • 6.3.4.1. Participant's Overview
      • 6.3.4.2. Financial Performance
      • 6.3.4.3. Product/Service Benchmarking
      • 6.3.4.4. Strategic Initiatives
    • 6.3.5. Elanco
      • 6.3.5.1. Participant's Overview
      • 6.3.5.2. Financial Performance
      • 6.3.5.3. Product/Service Benchmarking
      • 6.3.5.4. Strategic Initiatives
    • 6.3.6. Vetoquinol S.A
      • 6.3.6.1. Participant's Overview
      • 6.3.6.2. Financial Performance
      • 6.3.6.3. Product/Service Benchmarking
      • 6.3.6.4. Strategic Initiatives
    • 6.3.7. Phibro Animal Health Corporation
      • 6.3.7.1. Participant's Overview
      • 6.3.7.2. Financial Performance
      • 6.3.7.3. Product/Service Benchmarking
      • 6.3.7.4. Strategic Initiatives
    • 6.3.8. Norbrook
      • 6.3.8.1. Participant's Overview
      • 6.3.8.2. Financial Performance
      • 6.3.8.3. Product/Service Benchmarking
      • 6.3.8.4. Strategic Initiatives
    • 6.3.9. Dechra Pharmaceuticals Plc
      • 6.3.9.1. Participant's Overview
      • 6.3.9.2. Financial Performance
      • 6.3.9.3. Product/Service Benchmarking
      • 6.3.9.4. Strategic Initiatives
    • 6.3.10. Bimeda, Inc
      • 6.3.10.1. Participant's Overview
      • 6.3.10.2. Financial Performance
      • 6.3.10.3. Product/Service Benchmarking
      • 6.3.10.4. Strategic Initiatives
    • 6.3.11. Cargill, Incorporated
      • 6.3.11.1. Participant's Overview
      • 6.3.11.2. Financial Performance
      • 6.3.11.3. Product/Service Benchmarking
      • 6.3.11.4. Strategic Initiatives
  • 6.4. List of other key players

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Beef Cattle Health Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 4 U.S. Beef Cattle Health Market Estimates and Forecasts, by Vaccine, 2021 - 2033 (USD Million)
  • Table 5 U.S. Beef Cattle Health Market Estimates and Forecasts, by Pharmaceuticals, 2021 - 2033 (USD Million)
  • Table 6 U.S. Beef Cattle Health Market Estimates and Forecasts, by Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Commodity Flow Analysis
  • Fig. 7 Value Chain-Based Sizing & Forecasting
  • Fig. 8 QFD Model Sizing & Forecasting
  • Fig. 9 Bottom-Up Approach
  • Fig. 10 Market Snapshot
  • Fig. 11 Segment Snapshot 1
  • Fig. 12 Segment Snapshot 2
  • Fig. 13 Competitive Landscape Snapshot
  • Fig. 14 Parent Market Outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary Market Outlook, 2024 (USD Billion)
  • Fig. 16 U.S. Beef Cattle Health Market Dynamics
  • Fig. 17 Porter's Five Forces Analysis
  • Fig. 18 PESTEL Analysis
  • Fig. 19 U.S. Beef Cattle Health Market: Product Outlook and Key Takeaways
  • Fig. 20 U.S. Beef Cattle Health Market: Product Movement Analysis
  • Fig. 21 Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Attenuated Live Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Inactivated Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Subunit Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 DNA Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Recombinant Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Autogenous Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Other Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Parasiticides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Anti-infectives Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Anti-inflammatory Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Medicated Feed Additives Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. Beef Cattle Health Market: Distribution Channel Outlook and Key Takeaways
  • Fig. 38 U.S. Beef Cattle Health Market: Distribution Channel Movement Analysis
  • Fig. 39 Hospital/Clinic Pharmacy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Retail Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 E-commerce Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Key company categorization
  • Fig. 43 Product/Service heat map analysis
  • Fig. 44 Strategic framework